Shanghai Shen Lian Biomedical Corp (688098) — Working Capital to Net Assets Ratio
Shanghai Shen Lian Biomedical Corp (688098) has a Working Capital to Net Assets ratio of 26.6% as of March 2026. Working capital of CN¥371.31 Million (current assets of CN¥495.15 Million minus current liabilities of CN¥123.85 Million) is measured against net assets of CN¥1.40 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 688098 net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Shen Lian Biomedical Corp Working Capital to Net Assets (2013–2025)
This chart shows how Shanghai Shen Lian Biomedical Corp's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 26.6%, reflecting working capital of CN¥371.31 Million against net assets of CN¥1.40 Billion CNY. Check 688098 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Shen Lian Biomedical Corp from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Shanghai Shen Lian Biomedical Corp.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 28.8% | CN¥402.57 Million | CN¥1.40 Billion | CN¥535.90 Million | CN¥133.33 Million | ▼ -1.7 pp |
| 2024 | 30.5% | CN¥434.63 Million | CN¥1.43 Billion | CN¥550.83 Million | CN¥116.20 Million | ▼ -4.1 pp |
| 2023 | 34.6% | CN¥521.79 Million | CN¥1.51 Billion | CN¥598.29 Million | CN¥76.50 Million | ▼ -6.0 pp |
| 2022 | 40.6% | CN¥608.29 Million | CN¥1.50 Billion | CN¥705.50 Million | CN¥97.22 Million | ▼ -1.4 pp |
| 2021 | 42.1% | CN¥619.93 Million | CN¥1.47 Billion | CN¥733.46 Million | CN¥113.53 Million | ▼ -7.2 pp |
| 2020 | 49.3% | CN¥687.99 Million | CN¥1.40 Billion | CN¥793.86 Million | CN¥105.87 Million | ▼ -5.6 pp |
| 2019 | 54.9% | CN¥703.65 Million | CN¥1.28 Billion | CN¥849.98 Million | CN¥146.33 Million | ▲ +13.4 pp |
| 2018 | 41.6% | CN¥345.74 Million | CN¥831.94 Million | CN¥496.92 Million | CN¥151.18 Million | ▲ +11.6 pp |
| 2017 | 30.0% | CN¥164.70 Million | CN¥549.27 Million | CN¥283.61 Million | CN¥118.91 Million | ▲ +4.3 pp |
| 2016 | 25.7% | CN¥119.43 Million | CN¥465.47 Million | CN¥261.75 Million | CN¥142.32 Million | ▲ +0.6 pp |
| 2015 | 25.1% | CN¥79.60 Million | CN¥317.41 Million | CN¥252.50 Million | CN¥172.90 Million | ▲ +9.6 pp |
| 2014 | 15.5% | CN¥37.38 Million | CN¥241.57 Million | CN¥324.71 Million | CN¥287.32 Million | ▼ -28.6 pp |
| 2013 | 44.1% | CN¥144.55 Million | CN¥327.59 Million | CN¥348.49 Million | CN¥203.94 Million | — |